Recent Updates
Recently added Catalysts
VOR

Vor to Participate in Three Upcoming Investor Conferences

Key Takeaway: CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that members of its senior management team will be participating in three upcoming investor conferences: Cowen’s 42nd Annual Hea

Full Press Release Details

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that members of its senior management team will be participating in three upcoming investor conferences:
Cowen’s 42nd Annual Healthcare Conference
Presentation Date: Monday, March 7, 2022
Oppenheimer's 32nd Annual Healthcare Conference
Presentation Date: Tuesday, March 15, 2022
Barclays Global Healthcare Conference
Fireside Chat: Thursday, March 17, 2022
The live webcasts of the presentations and fireside chat will be available on the Company's website at www.vorbio.com. An archived replay of each webcast will also be available.
Vor Biopharma is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Vice President, Corporate Communications, Vor
Last updated: Feb 28, 2022